Genmarkører og nye behandlingsstrategier ved urogenital kreft (GATES)
- Prosjektnummer
- 911005
- Ansvarlig person
- Lars A. Akslen
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Oncogenesis & Cancer Research
- Forskningsaktivitet
- Translasjonsforskning
Frequency of the basal-like phenotype in African breast cancer.
APMIS 2007 Dec;115(12):1391-9.
PMID: 18184410
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.
Clin Cancer Res 2007 Dec;13(23):7003-11.
PMID: 18056176
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
BMC Cancer 2007;7():134. Epub 2007 jul 24
PMID: 17650314
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
Anal Biochem 2007 Jul;366(1):46-58. Epub 2007 mar 18
PMID: 17449007
Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Clin Cancer Res 2007 Feb;13(3):892-7.
PMID: 17289882
ERG upregulation and related ETS transcription factors in prostate cancer.
Int J Oncol 2007 Jan;30(1):19-32.
PMID: 17143509
Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
Int J Cancer 2006 Mar;118(5):1227-33.
PMID: 16152605
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer.
Virchows Arch 2006 Jan;448(1):68-74. Epub 2005 okt 12
PMID: 16220297
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
J Clin Oncol 2006 Jan;24(2):268-73. Epub 2005 des 5
PMID: 16330673
Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
BJU Int 2006 Jan;97(1):51-5.
PMID: 16336328
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Clin Cancer Res 2006 Feb;12(4):1168-74.
PMID: 16489070
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.
J Natl Cancer Inst 2006 Mar;98(5):316-25.
PMID: 16507828
Vascular proliferation is important for clinical progress of endometrial cancer.
Cancer Res 2006 Mar;66(6):3303-9.
PMID: 16540684
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.
FASEB J 2006 May;20(7):947-9. Epub 2006 apr 25
PMID: 16638967
Gene expression in poorly differentiated papillary thyroid carcinomas.
Thyroid 2006 Feb;16(2):161-75.
PMID: 16676402
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Am J Obstet Gynecol 2006 Oct;195(4):979-86. Epub 2006 mai 3
PMID: 16677592
Body size and thyroid cancer in two million Norwegian men and women.
Br J Cancer 2006 Aug;95(3):366-70. Epub 2006 jul 11
PMID: 16832414
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
Cell Cycle 2006 Aug;5(16):1779-87. Epub 2006 aug 15
PMID: 16931911
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Mol Cancer Ther 2006 Nov;5(11):2914-8.
PMID: 17121939
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
J Urol 2005 Feb;173(2):425-8.
PMID: 15643193
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Int J Oncol 2005 Feb;26(2):329-36.
PMID: 15645116
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
Oncol Rep 2005 Mar;13(3):525-30.
PMID: 15706428
Low frequency of BRAF and CDKN2A mutations in endometrial cancer.
Int J Cancer 2005 Jul;115(6):930-4.
PMID: 15723290
A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
Genes Chromosomes Cancer 2005 Sep;44(1):10-8.
PMID: 15880589
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.
Cancer Epidemiol Biomarkers Prev 2005 May;14(5):1108-12.
PMID: 15894660
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Clin Cancer Res 2005 Jun;11(11):4003-11.
PMID: 15930334
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
J Invest Dermatol 2005 Aug;125(2):312-7.
PMID: 16098042
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells.
Breast Cancer Res 2005;7(5):R634-44. Epub 2005 jun 14
PMID: 16168108
Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.
Br J Cancer 2005 Oct;93(8):933-8.
PMID: 16189525
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Clin Cancer Res 2005 Dec;11(24 Pt 1):8606-14.
PMID: 16361544
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
Cancer Res 2004 Feb;64(3):830-5.
PMID: 14871808
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.
J Clin Oncol 2004 Apr;22(7):1242-52.
PMID: 15051772
Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
Histopathology 2004 May;44(5):472-9.
PMID: 15139995
Lymphatic vessel density and prognosis in cutaneous melanoma.
Br J Cancer 2004 Sep;91(6):1224-5.
PMID: 15316566
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Clin Cancer Res 2004 Aug;10(16):5367-74.
PMID: 15328174
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series.
Int J Gynecol Cancer 2004 Sep-Oct;14(5):957-65.
PMID: 15361209
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Int J Oncol 2004 Dec;25(6):1559-65.
PMID: 15547691
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Int J Oncol 2004 Dec;25(6):1615-23.
PMID: 15547698
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.
Clin Cancer Res 2003 Apr;9(4):1474-9.
PMID: 12684422
Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
Gynecol Oncol 2003 Oct;91(1):218-25.
PMID: 14529685
MSI-low, a real phenomenon which varies in frequency among cancer types.
J Pathol 2003 Nov;201(3):389-94.
PMID: 14595750
Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
APMIS 2003 Nov;111(11):1011-8.
PMID: 14629267
A model of human tumor dormancy: an angiogenic escape from the nonangiogenic phenotype.
J Natl Cancer Inst. 2007;99(4):331-2 (response to correspondence).
Angiogenesis (Special Issue).
APMIS 2004;112 (7/8):399-549.
Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissu
American Association for Cancer Research 94th Annual Meeting, Toronto, Canada, April 4th – 9th, 2003
GENE EXPRESSION PROFILING IN PROSTATE CANCER: CLUSTER ANALYSIS AND ASSOCIATION WITH TUMOR DIFFERENTIATION.
4th Bergen Conference on Cancer Research, Solstrand Fjordhotell, May 9 – 10, 2003.
Comparison of DNA microarray and quantitative RT-PCR for quantitation of gene expression of selected genes in prostate cancer.
4th Bergen Conference on Cancer Research, Solstrand Fjordhotell, May 9 – 10, 2003.
GENE EXPRESSION PROFILING IN PROSTATE CANCER
Scandinavian Association of Urology in Bergen, Norway, June 11 - 13, 2003.
DNA microarray studies of human cancer – pitfalls and outlook.
Invited lecture Norwegian Biochemical Society, Geilo January 23th – 26st 2003 – “The Winter Meeting”.
Global analysis of gene expression and regulatory patterns in urogenital tumors using DNA microarrays.
Invited lecture, NorFa meeting on RNA regulation and metabolism, Amsterdam, October 31st to November 1st, 2003.
Mutation, methylation and expression analysis of the PTEN gene in a population-based series of endometrial carcinomas.
American Association for Cancer Research (AACR), Toronto, April 4-9, 2003.
Molecular and Prognostic Markers in Prostate Cancer. A study of cell-cycle regulators, angiogenesis and candidate markers
- Disputert:
- november 2007
- Hovedveileder:
- Lars A. Akslen
Biological Markers in Cutaneous Melanoma. A study with special focus on cell cycle regulation, cell adhesion proteins and tumor
- Disputert:
- mai 2007
- Hovedveileder:
- Lars A. Akslen
Biologic and Prognostic Markers of Endometrial Carcinoma. A study with special focus on cell-adhesion proteins, angiogenesis and
- Disputert:
- desember 2005
- Hovedveileder:
- Lars A. Akslen
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest